10:09 AM EDT, 09/11/2019 (MT Newswires) -- Adial Pharmaceuticals (ADIL) said Wednesday that it has successfully retested a previously manufactured supply of clinical trial packaged tablets of the investigational drug AD04 for the treatment of alcohol use disorder.
The company said tests showed that the clinical trial materials passed reevaluation and are eligible for use in the phase 3 trial.
The company has great information about it on their website with promising statisics.
The company said tests showed that the clinical trial materials passed reevaluation and are eligible for use in the phase 3 trial.
The company has great information about it on their website with promising statisics.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.